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Abstract
The involvement of GALNT12 in colorectal carcinogenesis has been demonstrated but it is
not clear to what extent it is implicated in familial CRC susceptibility. Partially inactivating
variant, NM_024642.4:c.907G>A, p.(D303N), has been previously detected in familial CRC
and proposed as the causative risk allele. Since phenotypes of the described carrier families
showed not only CRC but also a polyp history, we hypothesized that GALNT12 could be
involved in adenoma predisposition and consequently, in hereditary polyposis CRC syn-
dromes. For that purpose, we have screened the GALNT12 gene in germline DNA from 183
unrelated attenuated polyposis patients. c.907G>A, p.(D303N) was detected in 4 cases
(MAF = 1.1%) and no other candidate variants were found. After segregation studies, LOH
analyses, glycosylation pattern tests and case-control studies, our results did not support
the role of c.907G>A, p.(D303N) as a high-penetrance risk allele for polyposis CRC.
Introduction
Polypeptide N-acetylgalactosaminyltransferase 12 (GALNT12) is part of a large family of hexo-
syltransferases involved in the initial steps of mucin-type O-glycosylation process [1]. Alter-
ations in the activity of these enzymes lead to aberrant glycosylation, which has been
associated with alterations in cell growth, differentiation, transformation, adhesion, metastasis
and immune surveillance in cancers [2]. Particularly, GALNT12 is highly expressed in the
digestive tract [1] and it is frequently downregulated in colorectal cancer (CRC) [3].
Evidence on the association between GALNT12 (MIM#610290) and colorectal carcinogene-
sis had been reported when 6 fully and 1 partially inactivating variants were detected in hetero-
zygosis in the germline DNA of CRC patients, while no inactivating variants were detected in
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a cohort of cancer-free controls older than 70 [4]. Tumors from the 6 fully inactivating muta-
tion carriers showed aberrant glycosylation patterns of MUC1, main target of GALNT12 in
the digestive tract, providing evidence of their involvement in CRC carcinogenesis. However,
the variant NM_024642.4:c.907G>A, p.(D303N), which showed a partial activity of 37% com-
pared to the wild type protein was not tested, leaving its role in the genesis of CRC unclear.
Later on, c.907G>A, p.(D303N) was detected in three families fulfilling the Bethesda clinical
criteria for the identification of individuals at risk for Hereditary nonpolyposis colorectal can-
cer (HNPCC) along with a high polyp burden [5]. Authors proposed inactivating GALNT12
alleles, in particular, c.907G>A, p.(D303N), as high-predisposition risk alleles which could
explain part of the missing heritability of familial CRC. Recently, no functionally relevant
mutations at the GALNT12 locus were detected in a cohort of CRC type X (families fulfilling
the strict Amsterdam clinical criteria for the identification of HNPCC and displaying mis-
match-proficient tumors), what discarded this gene as a major predisposition gene for
HNPCC [6].
Adenomatous polyposis (AP) is characterized by the development of adenomas along the
large intestine and rectum, conferring a high risk of CRC. Therefore, it is a CRC-predisposi-
tion syndrome whose risk of cancer depends on the severity of the polyposis. The attenuated
forms of adenomatous polyposis (AAP) constitute a large and heterogeneous group in terms
of polyposis severity, family history, and genetic predisposition. Around 20% of AAP can be
explained by germline mutations in well-known high-penetrance predisposition genes, such as
APC and MUTYH [7] or the newly described POLE [8], POLD1 [8], NTHL1 [9] and MSH3
[10]. Nevertheless, the vast majority is still not explained, pointing to the involvement of other
unknown high-predisposition genes, polygenic inheritance consisting in the additive effect of
low-predisposition alleles or environmental factors.
Given that inactivating GALNT12 variants were detected in Bethesda families with a high
polyp burden [5], we hypothesized that GALNT12 could account for part of the unexplained
AAP susceptibility. Therefore, our aim is to contribute to the clarification of the role of
GALNT12 in the predisposition to familial polyposis CRC through the screening and charac-
terization of GALNT12 mutations in an unexplained AAP cohort.
Material and methods
Study cohort
Inclusion criteria were more than 20 accumulated or 10 synchronic adenomas regardless of
age or more than 10 adenomas before the age of 70. Previous detection of candidate variants in
any known CRC predisposition gene was established as exclusion criteria.
Germline DNAs from a total of 183 unrelated polyposis cases were included in the study;
127 subjects from Hospital Clı́nico San Carlos (Madrid), 37 from Hospital 12 de Octubre
(Madrid) and 19 from Grupo de Medicina Xenomica-USC (Galicia). Ethical approval was
obtained from Hospital Clı́nico San Carlos’ Ethical Research Committee (approval number: C:
P:-14/241-E_BS). A written informed consent was obtained from each participant.
GALNT12 mutational screening
The first 164 samples (Madrid) were screened through an NGS Haloplex custom panel (Agilent
Technologies, U.S.) of 22 CRC-related predisposition genes sequenced in a MiSeq System (Illu-
mina, U.S.) (Table 1). Data analysis and variant calling were performed with the SureCall soft-
ware (Agilent Technologies, U.S.). Exome data provided by Grupo de Medicina Xenomica-USC
(Galicia) was used to screen for GALNT12 variants in the remaining 19 samples. The exome
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enrichment system used was SureSelect Human All Exon v6 (Agilent Technologies) and sequenc-
ing was carried out in an Ion Proton System (Thermo Fisher Scientific, U.S.).
The filtering strategy is described in Fig 1. All rare (novel or MAF<0.01), deleterious or
possibly deleterious variants (according to protein and/or splicing alteration prediction tools)
were selected for validation by direct sequencing. MaxEnt and HSF [11] were used to predict
splicing alterations and SIFT [12], Polyphen2 [13] and MutationTaster [14] to predict protein
damage. GALNT12 candidate variants have been submitted to ClinVar, NCBI (https://www.
ncbi.nlm.nih.gov/clinvar/).
Segregation and LOH
Both loss of heterozygosity (LOH) in adenoma/tumor DNA and segregation analyses in the
germline DNA of family members were achieved by direct sequencing.
FFPE-immunohistochemistry
Immunohistochemistry of total and unglycosylated MUC1 was performed on 5 formalin-
fixed, paraffin-embedded (FFPE) matched normal and adenoma tissue sections. MUC1
(VU4H5) mouse monoclonal antibody (Cell Signaling Technology, U.S.), which binds to the
extracellular domain only if the threonine residue of the tandem repeat is not glycosylated, was
used to specifically detect non-glycosylated MUC1. MUC1 (EMA, E29) mouse monoclonal
antibody (DAKO, Thermo Fisher Scientific, U.S.), which reacts with the MUC1 cytoplasmic
domain, was used to detect total MUC1. Detection was done with the Dako Omnis Staining
System (DAKO) and slides were counterstained with hematoxylin. Two expert pathologists
reviewed all the staining. Levels of staining were classified into 0, +, ++, +++ according to the
antibody intensity.
Case-control study
Germline DNAs from 451 unrelated polyposis cases and 714 cancer-free controls were tested
for c.907G>A, p.(D303N) by TaqMan genotyping assays (Thermo Fisher Scientific, U.S.).
Data from the 1000 Genomes Project [15], Exome Variant Server [16] and Exome Aggregation
Consortium [17] was also used to check the association of c.907G>A, p.(D303N) with the
AAP cohort. Fisher’s exact test was used to assess differences in the allelic distribution between





APC 99.8% MSH4 100%
AXIN2 99.7% MSH6 99.98%
BMP4 100% MUTYH 100%
BMPR1A 98.82% NTHL1 100%
ENG 100% PMS2 99.22%
GALNT12 100% POLD1 100%
GREM1 100% POLE 99.68%
MLH1 100% PTEN 100%
MLH3 99.06% SCG5 99.87%
MSH2 100% SMAD4 100%
MSH3 100% STK11 100%
All coding regions, intron-exon boundaries and UTR regions of the listed genes were included in the custom panel
https://doi.org/10.1371/journal.pone.0187312.t001
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cohorts and CaTS [18] to estimate the statistical power. A ρ value of 0.05 was considered statis-
tically significant.
Results and discussion
Summary of the clinicopathological characteristics of the study and validation cohorts are
shown in Table 2.
Germline DNAs from 183 AAP patients (Table 2) were screened for mutations in the
GALNT12 gene. Identified variants are shown in S1 Table. After applying our filtering strategy
(Fig 1) only 4 cases were found to harbor the GALNT12 variant c.907G>A, p.(D303N) and no
other candidate GALNT12 variants were detected (S1 Table). c.907G>A, p.(D303N) carriers
were all screened by the 22-gene NGS panel, therefore carrier data from the remaining genes
Fig 1. Filtering strategy for the detection of candidate variants.
https://doi.org/10.1371/journal.pone.0187312.g001





Dx Age; average(range) 61 (32–79) 64.3 (30–85)
N adenoma; average (range) 30 (10–100) 20 (10–150)
Hyperplastic polyps 87 (47.5%) 60 (22.5%)
Full-blown AAPa 140 (76,5%) 164 (61.2%)
CRC 49 (26.7%) 78 (29.1%)
aFull-blown polyposis = subjects with more than 20 adenomas or 10 synchronic adenomas. The remaining
subjects presented between 10–20 adenomas.
https://doi.org/10.1371/journal.pone.0187312.t002
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was reviewed and filtered according to the same strategy, and no other candidate variants were
found in any other CRC susceptibility gene (S2 Table). All probands harboring c.907G>A (p.
D303N) presented full-blown late-onset AAP, and all of them had both adenoma and CRC
family history (Table 3).
Looking at public genome databases, c.907G>A, p.(D303N) is a rare allele present in less
than 0.3% of all tested populations, which makes a statistical difference with respect to the pol-
yposis study cohort (Table 4). Moreover, as it has been mentioned above, c.907G>A, p.
(D303N) had been previously described in CRC patients, functional characterization of the
encoded protein showed a partial activity of 37% when compared with the wild type protein
[4] and co-segregation with CRC and polyps was also described in families fulfilling the
Bethesda clinical criteria [5]. Together, all this data suggest that the c.907G>A, p.(D303N) var-
iant could be a quite good high-predisposition candidate allele for unexplained AAP. There-
fore, subsequent tests were performed in order to shed light on the polyposis causality of the
c.907G>A, p.(D303N) variant. For this purpose, segregation and LOH analyses, glycosylation
pattern tests and case-control studies were achieved.
Table 3. Clinical characteristics of c.907G>A, p.(D303N) carriers.
Family Id Inclusion criteria Dx agea No. of adenomas Cancer
type age
PAX1 I:1 20Ab 71 >50 no
PAX2 I:1 10SAc 80 12 no
PAX3 I:1 20Ab 50 >30 no
PAX4 I:1 20Ab 78 37 CRC/renal 78/76
aDx age: age at diagnosis of polyposis.
b20A = more than 20 adenomas
c10SA = 10 synchronic adenomas.
https://doi.org/10.1371/journal.pone.0187312.t003
Table 4. c.907G>A, p.(D303N) allelic population frequencies and association analysis.
POPULATION N ALTg REFh MAF ρ-value OR
AAPa 183 4 362 0,011
1000Gb 503 3 1003 0.003 0.087 3.69
EVSc 4300 1 8589 0.001 0.003 8.63
ExACd 31072 122 62022 0.002 0.007 5.62
HCSCe 714 4 1424 0.003 0.059 3.93
VALf 268 0 536 0
HCSC 714 4 1424 0.003 0.41 0.2950
AAP+VAL 451 4 898 0,004
HCSC 714 4 1424 0.003 0.496 1.59
aAAP = attenuated adenomatous polyposis study cohort.
b1000G = European population from the 1000 Genomes database.
cEVS = European-American population from the Exome Variant Server.
dExAC = Non-Finnish European population from the Exome Aggregation Consortium database.
eHCSC = cancer-free control population recruited at Hospital Clı́nico San Carlos (Madrid).
fVAL = validation cohort.
gALT = altered allele count
hREF = reference allele count.
https://doi.org/10.1371/journal.pone.0187312.t004
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First, the variant was tested in the germline DNA of those relatives who had agreed to par-
ticipate in the study. None of the three families tested for segregation showed a clear high-pen-
etrance allele segregation pattern (Fig 2). There was only one relative with polyposis diagnosis
(pedigree PAX1_II:8) and she harbored the variant. In pedigrees PAX1 and PAX2, there were
two relatives with a diagnosis of adenomas and they didn’t harbor the variant. Conversely, two
relatives in pedigrees PAX2 and PAX4 harbored the variant and they didn’t show any ade-
noma at the ages of 58 and 47.
Since all probands showed late-onset AAP and most of the healthy relatives tested were in
their forties, carriers who had not developed polyposis could still develop it at later ages.
Fig 2. Pedigrees of families harboring c.907G>A (p.D303N) and segregation analysis. Probands are marked with arrows. MUT = individual carrying
the c.907G>A (p.D303N) allele. WT = individual not carrying the c.907G>A, p.(D303N) allele. CRC = colorectal cancer. y = age at diagnosis or age at the
time of DNA extraction (in healthy subjects).
https://doi.org/10.1371/journal.pone.0187312.g002
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However, it is noteworthy that 2 relatives had already developed some adenomas at younger
ages (Fig 2: PAX1_III:1 and PAX2_III:3) and none of them harbored the c.907G>A (p.
D303N) variant. Described frequencies of adenomas in populations ranging from 40 to 50
years is around 4% [19, 20] so these cases could be explained as phenocopy phenomena, but
within a context of suspected polyposis genetic predisposition we would not expect to have
many cases of adenomas at early ages that are not explained by the putative polyposis suscepti-
bility cause. Clarke et al. also observed similar results in two Bethesda families harboring the
variant [5]. They observed two polyp cases and one CRC in which the variant was not detected.
Therefore, considering both studies, co-segregation results are inconclusive.
Guda et al. [4] suggest that CRC associated GALNT12 complete inactivation alleles are most
likely to act as simple null allele rather than dominant effect or oncogenic alleles. Conse-
quently, LOH events were investigated in 3 low-grade dysplastic adenomas, 2 high-grade dys-
plastic adenomas and 1 CRC (Table 5). No LOH of the c.907G>A, p.(D303N) allele was
detected in any of the samples. It was not possible, though, to achieve full GALNT12 somatic
mutational screening and methylation analysis, so we cannot discard other somatic second
hits at GALNT12 or haplosinsuffiency mechanisms leading to the adenoma development. In
any case, we would expect a decrease in GALNT12’s activity and therefore to an increase in
improperly glycosylated or unglycosylated proteins in carrier adenomas. In order to test
this, two antibodies against both, total and unglycosylated forms of GALNT12’s target pro-
tein MUC1, were tested to detect any change in the glycosylation pattern of the same 5 ade-
nomas tested for LOH and their matched normal tissues similarly to Guda et al. [4]. Any
alteration in the glycosylation activity would imply an increase in the amounts of unglycosy-
lated but not total MUC1 levels. However, no differences were detected in any of the ade-
noma-normal tissue pairs (Table 5 and S1 Fig), ruling out the causality of this allele in the
adenoma development.
Taken together, these results make us distrust c.907G>A, p.(D303N) as a high-predisposi-
tion allele for AAP. Nevertheless, due to the high association of the variant with the study
cohort and in order to validate the previous results, a case-control study was conducted in a
larger validation cohort with the same inclusion criteria (Table 2) and a home cancer-free con-
trol cohort. In this case, the statistical analysis did not detect significant differences on the
c.907G>A, p.(D303N) allele frequency between cohorts (Table 4). The clinical information
about the 4 controls harboring the c.907G>A, p.(D303N) allele was further investigated. Two
of them died at old age without any personal or familial history of adenomas. One other con-
trol had two second-degree relatives with late onset CRC (>70), but underwent several colo-
noscopies with no adenomas detected. And the last one had a melanoma diagnosis at the age
of 42.
Table 5. Adenomas tested for LOH and MUC1 IHC.
Family Patient Adenoma Histology LOH IHC-Na IHC-Tb
PAX1 I:1 12B3204 Low-grade tubulovillous adenoma NO ++/+++ ++/+++
13B12094 Low-grade tubular adenoma NO ++/+++ ++/+++
PAX2 I:1 9B66481 High-grade tubular adenoma NO ++/+++ ++/+++
9B66483 Low-grade tubular adenoma NO ++/+++ ++/+++
PAX3 I:1 16B23342 High-grade tubular adenoma NO ++/+++ ++/+++
15B10052 Adenocarcinoma Haggitt 4 NO
aIHC-N = IHC evaluation for matched-normal tissues (ratio between non-glycosylated MUC1 and total MUC1 levels)
bIHC-T = Immunochemistry evaluation for matched-adenomatous tissue (ratio between non-glycosylated MUC1 and total MUC1 levels).
https://doi.org/10.1371/journal.pone.0187312.t005
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It should be noted, though, that due to the low frequency of the variant in control popula-
tions, the sample size used in this analysis allow us to detect statistical significance with a mini-
mum statistical power of 80% when the OR is greater than 4. Therefore, the case-control
analysis discards the c.907G>A, p.(D303N) variant as a high-penetrance risk allele for AAP, but
not as a low-penetrance allele. Our results discard the causality of c.907G>A, p.(D303N) in
hereditary polyposis CRC syndromes but not the role of the variant as a modifier allele or its
involvement in other forms of sporadic polyposis, which points to the necessity of larger sample
sizes to be able to further confirm or discard the role of this variant as a low-penetrance allele.
These results, together with the absence of other functionally relevant GALNT12 mutations
in our cohort, discard GALNT12 as a major high-predisposition gene for adenomatous polypo-
sis. Considering that its major role as a high-predisposition allele for HNPCC had been previ-
ously discarded [6], its major role in hereditary CRC syndromes can be ruled out.
With the development of next-generation sequencing technologies and their integration in
diagnosis laboratories, the screening of candidate high-predisposition genes that have been
proposed, but not validated, is an attractive but very dangerous tool for the understanding of
those unexplained familial cancer cases. Hence, the elucidation of cancer-risk candidate genes
and variants becomes essential to avoid clinical misinterpretation of cancer risk estimations in
carrier families. Here we show how an initially good high-risk candidate variant for polyposis
predisposition is finally dismissed after complementary assays. Finally, the role of GALNT12 as
a major high-predisposition gene for inherited CRC is not confirmed, and the inclusion of
GALNT12 in the screening of high-penetrance alleles in unexplained familial CRC is
discouraged.
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